Company Email Format Management

Curevo Vaccine

Biotechnology Research 21540 30th Dr Se 43 employees

Employees: 43
Contacts: 4
Emails: 4
Phones: 1

curevovaccine.com LinkedIn Crunchbase

Curevo Vaccine Overview

Headquarters: 21540 30th Dr Se
Phone Number: Available in AeroLeads
Website: curevovaccine.com
Industry: Biotechnology Research
Employees: 43
Founded: 2017
Funding: 110.0M
Company Email: Available in AeroLeads
NAICS: Research and Development in Biotechnology (except Nanobiotechnology)

Keywords

Vaccines Adjuvants Public Health Infectious Disease Drug Discovery Drug Development Immunology Clinical Trials

About Curevo Vaccine

Curevo Vaccine is a clinical-stage developer of vaccines for varicella and herpes zoster. Amezosvatein (CRV-101) is an adjuvanted subunit (non-mRNA) vaccine designed to prevent herpes zoster, commonly known as shingles. Our goal with a new herpes zoster vaccine is to improve the patient experience and, ultimately, overall vaccination rates, by developing amezosvatein as a vaccine with non-inferior efficacy combined with clinically-meaningful improvements in reactogenicity when compared to Shingrix.

Curevo Vaccine Contact Details

People in AeroLeads: 4
With contact data: 4
Email contacts: 4; 100.0% coverage
Phone contacts: 1; 25.0% coverage

Curevo Vaccine Org Chart

Sample employees and titles

Name	Title	Location	Contact
Ron Taylor		Seattle, Washington, United States	Email
Tamra Madenwald	Global Clinical Operations	Seattle, Washington, United States	Email Phone
Trina Slabiak, Ms, Rac		San Francisco, California, United States	Email
George Simeon	CEO at Curevo Vaccine Inc.	Greater Seattle Area, United States	Email